EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics

Timothy A Bates iD, Sintayehu K Gurmessa, Jules B Reyes-Weinstein, Eric Barklis, Fikadu G Tafesse iD

Biosensors · 22.02.2026 · 16 (2) · 132

DOI: 10.3390/bios16020132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors, online erschienen am 22.02.2026. Verfasst von Timothy A Bates und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Single-Domain Antibodies, SARS-CoV-2, Biosensing Techniques, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, US National Institutes of Health, Silver Innovation Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lateral flow assays (LFAs) are among the most successful technologies for point-of-care and at-home testing, but further advances are needed to reduce costs and accelerate development. Alpaca-derived nanobodies (Nbs), single-domain antibody fragments, are promising immunoassay reagents across diverse applications. Their small size and ease of recombinant production make them particularly well suited for diagnostics. Here, we present a paper-based LFA targeting the SARS-CoV-2 nucleocapsid (N) protein that exclusively uses Nbs for direct antigen detection. We also demonstrate in-house synthesis of Nb-coated gold nanoparticles, enabling instrument-free visual readout and detection of N protein down to 40 ng/mL. This design avoids components that require mammalian cell culture and can be produced entirely from in-house reagents, simplifying manufacturing and lowering component costs. Because the assay is read visually without an external reader, it is well suited for deployment in resource-limited settings. Together, these results highlight the speed and practicality of developing Nb-based LFAs and suggest a broadly applicable strategy for detecting other clinically important disease biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesSARS-CoV-2Biosensing TechniquesCOVID-19Coronavirus Nucleocapsid ProteinsPoint-of-Care TestingAnimalsHumansImmunoassayRapid Diagnostic TestsMetal NanoparticlesGoldCamelids, New WorldPoint-of-Care SystemsPhosphoproteins

Stichwörter der Autor:innen

lateral flow assaynanobodynucleocapsidpoint-of-care

Substanzen

Single-Domain AntibodiesGoldCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteins

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, OR 97239, USA.
  • Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR 97239, USA.

ORCID-Profile: Timothy A Bates, Fikadu G Tafesse

Förderung

  • NIAID NIH HHS
  • US National Institutes of Health
  • Silver Innovation Award
  • Oregon Health & Science University Biophysics Shared Resources Core and equipment

Zitieren

APA

Bates, T. A., Gurmessa, S. K., Reyes-Weinstein, J. B., Barklis, E., & Tafesse, F. G. (2026). A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics. Biosensors, 16(2), 132. https://doi.org/10.3390/bios16020132

Vancouver

Bates TA, Gurmessa SK, Reyes-Weinstein JB, Barklis E, Tafesse FG. A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics. Biosensors. 2026;16(2):132. doi:10.3390/bios16020132

BibTeX
@article{Bates2026,
  author = {Bates, Timothy A and Gurmessa, Sintayehu K and Reyes-Weinstein, Jules B and Barklis, Eric and Tafesse, Fikadu G},
  title = {A Nanobody-Based Lateral Flow Assay for Point-of-Care Diagnostics},
  journal = {Biosensors},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {132},
  doi = {10.3390/bios16020132}
}
Kostenlos starten →